| |
| NASH |Abstract Library |
 |
| |
| The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors. |
| Abstract Details |
 |
|
| |
| |
| |
|
|
| |
Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease |
|
|
|
|
| |
Gastroenterol. 2020 May 25. doi: 10.14309/ajg.0000000000000676. Online ahead of print.
Ramy Younes 1 2, Olivier Govaere 2, Salvatore Petta 3, Luca Miele 4 5, Dina Tiniakos 2, Alastair Burt 2, Ezio David 6, Fabio M Vecchio 4 7, Marco Maggioni 8, Daniela Cabibi 9, Anna L Fracanzani 10, Chiara Rosso 1, Maria J Garcia Blanco 11, Angelo Armandi 1, Gian Paolo Caviglia 1, Marco Y W Zaki 2 12, Antonio Liguori 4, Paolo Francione 10, Grazia Pennisi 3, Antonio Grieco 4 5, Luca Valenti 13, Quentin M Anstee 2 14, Elisabetta Bugianesi 1
|
| |
|
|
| |
Author information
- 1Department of Medical Sciences, Division of Gastroenterology and Hepatology, A.O. Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.
- 2The Newcastle Liver Research Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.
- 3Sezione di Gastroenterologia, Dipartimento Biomedico di Medicina Interna e Specialistica, Università di Palermo, Palermo, Italy.
- 4Università Cattolica del Sacro Cuore, Rome, Italy.
- 5Area Medicina Interna, Gastroenterologia e Oncologia Medica, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy.
- 6Department of Pathology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, University of Turin, Turin, Italy.
- 7Area Anatomia Patologica, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.
- 8Department of Pathology, Ca' Granda IRCCS Foundation, Milan, Italy.
- 9Pathology Institute, PROMISE, University of Palermo, Palermo, Italy.
- 10Unit of Medicine and Metabolic Disease, Department of Pathophysiology and Transplantation, Ca' Granda IRCCS Foundation, Policlinico Hospital, University of Milan, Milan, Italy.
- 11Hospital Universitario de La Princesa, Medicina Interna, Madrid, Spain.
- 12Biochemistry Department, Faculty of Pharmacy, Minia University, Minya, Egypt.
- 13Translational Medicine, Department of Transfusion Medicine and Hematology, Fondazione IRCCS C'a Granda Ospedale Maggiore Policlinico, Milan, Italy.
- 14Newcastle NIHR Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.
Abstract
Introduction: We investigated the longitudinal impact of antinuclear antibody (ANA) on clinical outcomes and survival in nonalcoholic fatty liver disease (NAFLD).
Methods: ANA were found in 16.9% of 923 biopsy-proven NAFLD patients, but none of them had histologic autoimmune hepatitis (AIH) or developed AIH after a mean follow-up of 106±50 months.
Results: Although ANA-positive cases had a higher prevalence of nonalcoholic steatohepatitis at baseline, the occurrence of liver-related events, hepatocellula carcinoma, cardiovascular events, extrahepatic malignancy, and overall survival were similar to ANA-negative.
Discussion: Once AIH has been ruled out, the long-term outcomes and survival are unaffected by the presence of ANA in patients with NAFLD.
|
|
|
|
| |
| |
|
| |
|
|
|
|
|
